AstraZeneca's second-quarter results met expectations with sales up 17%, but higher expenses disappointed investors

From Morningstar: 2024-07-25 20:40:00

AstraZeneca’s second-quarter results met expectations, with total sales up 17%, but higher operating expenses may have disappointed investors. Sales growth may slow due to generic pressures on key drugs, while the cancer division continues to perform well. The company aims for $80 billion in sales by 2030, but achieving this goal remains uncertain. Morningstar metrics show a fair value estimate of £124.00, a wide economic moat rating, and medium uncertainty.



Read more at Morningstar: AstraZeneca Earnings: Steady Outlook but Growth…